Advanced urothelial carcinoma
Conditions
Interventions
Trade Name: Evoltra 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Clofarabine
CAS Number: 123318-82-1
Concent
Sponsors
Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patients with histologically or cytologically confirmed urothelial carcinoma, radiologically documented metastatic or unresectable locally advanced disease • Age = 18 years • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 • Absolute neutrophil count (ANC) greater than or equal to 1500. • White blood cell (WBC) count greater than 3.0. • Platelets greater than or equal to 100. • Hemoglobin greater than 9.0 g/dL. • Adequate hepatobiliary function as indicated by the following laboratory values: Total bilirubin = 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN • Adequate renal function as indicated by the following laboratory values: Serum creatinine = 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be > 60 mL/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation • Adequate cardiac function (NYHA cardiac III-IV excluded) • Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment • Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment. • Willing and able to provide informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 40
Exclusion criteria
Exclusion criteria: • Received previous treatment with clofarabine • Current concomitant chemotherapy, radiation therapy, or immunotherapy • Prior radiation therapy to the pelvis • Currently participation in other investigational drug studies or having received other investigational drugs within the previous 30 days • Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment. In particular: a) New York Heart Association classification stage II, III, or IV congestive heart failure; b) Coronary artery disease or arteriosclerotic cardiovascular disease (angina, myocardial infraction) within 3 months of first dose of study drug; c) Any other primary cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia. • Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). • Any medical condition that requires chronic use of oral high-dose corticosteroids (in excess of 1 mg/kg/day) (low-dose corticosteroid for pre-medication purposes are allowed). • Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results • Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed • Had currently active gastrointestinal disease, or prior surgery that might affect the ability of the participants to absorb oral Clofarabine. • Had prior treatment with a known nephrotoxic drug within 2 weeks of the first dose of study drug, unless the participants had a calculated GFR >30 at 2 time points no <7 days apart during the 2-week period prior to the first dose of study drug. • Positive human immunodeficiency virus (HIV) test. • Female patients who are pregnant/breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To define maximum tolerated dose (MTD) of Clofarabine in patients with metastatic or locally advanced urothelial carcinoma ;Secondary Objective: •To characterize the pharmacokinetics of Clofarabine in patients with metastatic or locally advanced urothelial carcinoma •To assess efficacy of Clofarabine in patients with metastatic or locally advanced urothelial carcinoma •To assess safety and tolerability of Clofarabine in patients with metastatic or locally advanced urothelial carcinoma ;Primary end point(s): Maximum tolerated dose;Timepoint(s) of evaluation of this end point: N/A | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Pharmacokinetics including maximum serum concentration (Cmax) and area under the concentration-time curve (AUC) over the dosing interval • Objective response (OR) determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Duration of response (DOR) (radiographic) • Time to progression (radiographic) • Progression-free survival (PFS) • Overall survival (OS) • Treatment-related adverse events ;Timepoint(s) of evaluation of this end point: N/A | — |
Countries
Austria
Contacts
Public ContactDepartement of Urology
Medical University of Vienna
Outcome results
None listed